Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

It’s one of several agreements with major vaccine makers as the UK hedges its bets over which of the shots will get okayed by regulators first. Novavax’s study is expected to recruit up to ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...

Novavax is also progressing well with its preclinical pipeline, which includes vaccines for RSV and H5N1 ... which provides a great opportunity to get in on the ground floor.

(Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce ...

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect ... Concerned about the content? Get in touch with us ...

Thus, it is worth knowing the facts that could determine the stock's prospects. Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today ...